OncoMatch/Clinical Trials/NCT07174583
A Study of IDE849 in Patients With DLL3 Expressing Tumors Including Small Cell Lung Cancer
Is NCT07174583 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1/2 trial studies multiple treatments including IDE849 and durvalumab for small-cell lung cancer.
Treatment: IDE849 · durvalumab · IDE161 — This is Phase 1/2, multicenter, clinical study to evaluate the safety, efficacy, PK, and immunogenicity of IDE849 in subjects with DLL3-expressing tumors including SCLC.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Other
Cancer type
Small Cell Lung Cancer
Neuroendocrine Tumor
Tumor Agnostic
Biomarker criteria
Required: DLL3 expression (positive)
Disease stage
Required: Stage IV
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: platinum-based chemotherapy
For SCLC, this includes platinum-based therapy
Must have received: anti-PD-1 therapy
programmed death-1/programmed death-ligand 1 inhibitors (except for subjects who refuse or are judged by the Investigator to be unsuitable for immunotherapy)
Cannot have received: DLL3 antibody-drug conjugate
prior treatment with DLL3 ADC
Cannot have received: topoisomerase I inhibitor
prior treatment with a topoisomerase I inhibitor including an ADC with a topoisomerase I inhibitor payload
Lab requirements
Blood counts
adequate bone marrow function
Kidney function
adequate organ function
Liver function
adequate organ function
Have adequate bone marrow and organ function.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Sarah Cannon Research Institute at HealthONE · Denver, Colorado
- Mayo Clinic Hospital - Florida · Jacksonville, Florida
- Sarah Cannon Research Institute at Florida Cancer Specialists · Orlando, Florida
- Piedmont Physicians Medical Oncology - Atlanta · Atlanta, Georgia
- The University of Chicago Medical Center - Duchossois Center for Advanced Medicine · Chicago, Illinois
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT07174583 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior DLL3 antibody-drug conjugate, topoisomerase I inhibitor disqualifies patients from enrollment.
Does this trial require DLL3?
Yes, DLL3 expression is a required biomarker for enrollment.
What disease stage is eligible?
Stage IV is required.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify